PofoliaShared via Pofolia

BMC Microbiology· 2026Q1

Public antibiotic resistance mechanisms in Salmonella can maintain inhibition by probiotics during antibiotic treatment

Gitta De Wit, Tom E. R. Belpaire, Ines Mandić-Mulec, Bram Lories et al.

Short summary

Salmonella Typhimurium expressing public antibiotic resistance mechanisms, like beta-lactamase, can protect co-administered probiotic bacteria (E. coli Nissle 1917, Bacillus subtilis) from otherwise inhibitory antibiotic concentrations (cefotaxime), preserving the probiotic's ability to inhibit Salmonella.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Pathogens with public antibiotic resistance mechanisms can protect co-administered probiotics from antibiotics.
  • Salmonella Typhimurium expressing beta-lactamase protected E. coli Nissle 1917 and Bacillus subtilis from cefotaxime.
  • Probiotics retained their inhibitory effect on Salmonella even in the presence of high antibiotic concentrations.
  • This mechanism allows for synergistic probiotic-antibiotic treatments.

AI-generated from the title and abstract; the full text is not read.

Abstract

Probiotics are being explored as a sustainable alternative to antibiotics that can also inhibit antibiotic-resistant pathogens. However, probiotics generally show a lower killing efficacy against susceptible pathogens compared to traditional antibiotics. Combining probiotics with antibiotics could provide a solution: the antibiotic effectively clears infection caused by non-resistant pathogens, whereas the probiotic helps control infections involving antibiotic-resistant strains. However, since probiotic strains preferentially do not carry antibiotic-resistance mechanisms themselves in order to limit the further spread of antibiotic resistance, combinatorial treatment would also inhibit the probiotic, thereby severely limiting its efficacy. We explore the potential of a novel combination therapy that aims to exploit public antibiotic resistance mechanisms commonly found in pathogens. These public resistance mechanisms, such as β-lactamase enzymes and chloramphenicol acetyltransferases, can protect nearby susceptible cells from the antibiotic by detoxifying the local environment. We demonstrate that a β-lactamase-producing Salmonella Typhimurium can protect two distinct probiotic bacteria, Escherichia coli Nissle 1917 and Bacillus subtilis , against high concentrations of cefotaxime across a range of in vitro conditions, maintaining the inhibitory effect of the probiotic on Salmonella. We show that susceptible probiotic strains can retain their activity in the presence of otherwise inhibitory antibiotic concentrations by exploiting β-lactamase-mediated detoxification by Salmonella Typhimurium. These findings provide a conceptual framework for designing synergistic probiotic–antibiotic treatments, offering a potentially promising strategy for managing infections in the context of rising antibiotic resistance.

The authors' abstract, as published at the source. BMC Microbiology, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Food Science

Food ScienceAgricultural and Biological Sciences